PET molecular imaging for pathophysiological visualization in Alzheimer's disease

Jing Wang,Chentao Jin,Jinyun Zhou,Rui Zhou,Mei Tian,Hyeon Jeong Lee,Hong Zhang

DOI: https://doi.org/10.1007/s00259-022-05999-z

2022-11-15

Abstract:Alzheimer's disease (AD) is the most common dementia worldwide. The exact etiology of AD is unclear as yet, and no effective treatments are currently available, making AD a tremendous burden posed on the whole society. As AD is a multifaceted and heterogeneous disease, and most biomarkers are dynamic in the course of AD, a range of biomarkers should be established to evaluate the severity and prognosis. Positron emission tomography (PET) offers a great opportunity to visualize AD from diverse perspectives by using radiolabeled agents involved in various pathophysiological processes; PET imaging technique helps to explore the pathomechanisms of AD comprehensively and find out the most appropriate biomarker in each AD phase, leading to a better evaluation of the disease. In this review, we discuss the application of PET in the course of AD and summarized radiolabeled compounds with favorable imaging characteristics.

radiology, nuclear medicine & medical imaging

What problem does this paper attempt to address?

The problems that this paper attempts to solve are the pathophysiological mechanisms of Alzheimer's disease (AD) and the evaluation of its biomarkers. Specifically, the paper explores the application of Positron Emission Tomography (PET) in Alzheimer's disease, especially by using radiolabeled agents to visualize different pathophysiological processes of AD. The paper aims to use PET technology to:

1. **Comprehensively explore the pathological mechanisms of AD**: Through a variety of radiolabeled agents, PET imaging technology can observe the pathological changes of AD from multiple perspectives, such as amyloid - β (Aβ) deposition, tau protein aggregation, abnormal glucose metabolism, etc., so as to understand the pathogenesis of AD more deeply.

2. **Find the most appropriate biomarkers for different AD stages**: Since AD is a multi - faceted and heterogeneous disease, and most biomarkers change dynamically during the AD process, it is necessary to establish a series of biomarkers to evaluate the severity and prognosis of the disease. PET imaging technology is helpful to find the most appropriate biomarkers for each AD stage.

3. **Improve the early diagnosis, disease progression monitoring and treatment effect evaluation of AD**: PET imaging technology can not only assist in the early diagnosis of AD, but also be used to monitor the development process of the disease and evaluate the effectiveness of treatment methods.

4. **Promote the application of non - invasive monitoring means**: Compared with traditional invasive detection methods (such as cerebrospinal fluid detection), PET imaging provides a non - invasive monitoring means, which can capture subtle pathophysiological changes in the early stage of the disease and is of great significance for AD research and clinical management.

In summary, by reviewing the application of PET molecular imaging technology in AD research, this paper aims to provide new perspectives and tools for the early diagnosis, disease progression monitoring and treatment effect evaluation of AD.